{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:49:16Z","timestamp":1791586156228,"version":"4.3.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CDC73 is a canonical tumor suppressor; however, its biological functions in lung adenocarcinoma (LUAD) and the extracellular vesicle (EV)-mediated mechanisms through which it exerts its effects remain unclear. In this study, we systematically evaluated the diagnostic value, biological functions, and EV-mediated regulatory roles of CDC73 in LUAD. First, quantitative proteomic analysis was performed on plasma-derived EVs from six patients with early-stage LUAD and three healthy donors, followed by further validation of EV-borne CDC73 expression in plasma-derived EV samples from eight LUAD patients and eight healthy donors. We found that the level of EV-borne CDC73 protein (EV-CDC73) was significantly reduced in LUAD, indicating its potential value as a diagnostic liquid-biopsy biomarker. To define its functional role, we established LUAD cell lines stably overexpressing CDC73 (A549^OE and H1299^OE) and performed rescue experiments in combination with PTEN knockdown using siRNA. The tumor-suppressive effects of CDC73 were systematically assessed through experiments examining cell proliferation, cell-cycle progression, apoptosis, migration, and related molecular mechanisms. Meanwhile, EVs were isolated by ultracentrifugation from the conditioned media of A549, H1299, and human bronchial epithelial (HBE) cells to analyze the effects of EVs with different CDC73 levels on recipient A549 and HBE cells, and xenograft models were used for in vivo validation. The results showed that CDC73 overexpression markedly inhibited LUAD cell proliferation and migration, induced G1-phase arrest, and promoted apoptosis. Mechanistically, CDC73 exerted its tumor-suppressive effects by upregulating PTEN and inhibiting AKT activation, whereas PTEN knockdown partially reversed these effects. In vivo experiments further confirmed that CDC73 overexpression suppressed tumor growth and migration. In addition, EVs derived from LUAD cells with high CDC73 expression showed a reduced ability to induce malignant transformation-related phenotypes in HBE cells and suppressed the PTEN\/AKT signaling axis; conversely, EVs derived from HBE cells with high CDC73 expression inhibited the malignant progression of LUAD cells. Collectively, CDC73 suppresses the malignant progression of LUAD through the PTEN\/AKT signaling axis, while EV-borne CDC73 not only has potential diagnostic value but also directly regulates malignant phenotypes in recipient cells, highlighting its translational potential in the diagnosis and treatment of LUAD.<\/jats:p>","DOI":"10.1038\/s41420-026-03305-6","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:25:00Z","timestamp":1786721100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CDC73 suppresses lung adenocarcinoma via the PTEN\/AKT pathway and exhibits biomarker and functional potential in extracellular vesicles"],"prefix":"10.1038","volume":"12","author":[{"given":"Hao","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongjun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7409-1580","authenticated-orcid":false,"given":"Tian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4447-1053","authenticated-orcid":false,"given":"Yi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"3305_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3305_CR2","first-page":"409","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72:409\u201336.","journal-title":"CA Cancer J Clin"},{"key":"3305_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","volume":"5","author":"C Zappa","year":"2016","unstructured":"Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5:288\u2013300.","journal-title":"Transl Lung Cancer Res"},{"key":"3305_CR4","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1128\/MCB.25.2.612-620.2005","volume":"25","author":"O Rozenblatt-Rosen","year":"2005","unstructured":"Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, Shanmugam KS, Copeland TD, Guszczynski T, et al. The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol. 2005;25:612\u201320.","journal-title":"Mol Cell Biol"},{"key":"3305_CR5","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1128\/MCB.17.3.1160","volume":"17","author":"X Shi","year":"1997","unstructured":"Shi X, Chang M, Wolf AJ, Chang C-H, Frazer-Abel AA, Wade PA, et al. Cdc73p and Paf1p are found in a novel RNA polymerase II-containing complex distinct from the Srbp-containing holoenzyme. Mol Cell Biol. 1997;17:1160\u20139.","journal-title":"Mol Cell Biol"},{"key":"3305_CR6","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/sj.onc.1208274","volume":"24","author":"GE Woodard","year":"2005","unstructured":"Woodard GE, Lin L, Zhang JH, Agarwal SK, Marx SJ, Simonds WF. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1\/PRAD1 expression. Oncogene. 2005;24:1272\u20136.","journal-title":"Oncogene"},{"key":"3305_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1530\/EC-13-0046","volume":"2","author":"F Cetani","year":"2013","unstructured":"Cetani F, Banti C, Pardi E, Borsari S, Viacava P, Miccoli P, et al. CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocr Connect. 2013;2:186\u201395.","journal-title":"Endocr Connect"},{"key":"3305_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/jcp.2007.048694","volume":"61","author":"S Selvarajan","year":"2008","unstructured":"Selvarajan S, Sii LH, Lee A, Yip G, Bay BH, Tan MH, et al. Parafibromin expression in breast cancer: a novel marker for prognostication? J Clin Pathol. 2008;61:64\u20137.","journal-title":"J Clin Pathol"},{"key":"3305_CR9","doi-asserted-by":"publisher","first-page":"1773.","DOI":"10.3390\/jcm11071773","volume":"11","author":"M-K Kim","year":"2022","unstructured":"Kim M-K. Parafibromin is highly expressed in hepatocellular carcinoma and its expression correlates with poor prognosis. J Clin Med. 2022;11:1773.","journal-title":"J Clin Med"},{"key":"3305_CR10","doi-asserted-by":"publisher","first-page":"23603","DOI":"10.18632\/oncotarget.15377","volume":"8","author":"HC Zheng","year":"2017","unstructured":"Zheng HC, Liu JJ, Li J, Wu JC, Yang L, Zhao GF, et al. The in vitro and vivo effects of nuclear and cytosolic parafibromin expression on the aggressive phenotypes of colorectal cancer cells: a search of potential gene therapy target. Oncotarget. 2017;8:23603\u201312.","journal-title":"Oncotarget"},{"key":"3305_CR11","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1007\/s13277-015-4103-x","volume":"37","author":"DF Shen","year":"2016","unstructured":"Shen DF, Liu X, Yang XF, Fang L, Gao Y, Zhao S, et al. The roles of parafibromin expression in ovarian epithelial carcinomas: a marker for differentiation and prognosis and a target for gene therapy. Tumor Biol. 2016;37:2909\u201324.","journal-title":"Tumor Biol"},{"key":"3305_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4132\/jptm.2015.08.10","volume":"49","author":"S Karaarslan","year":"2015","unstructured":"Karaarslan S, Yaman B, Ozturk H, Kumbaraci BS. Parafibromin staining characteristics in urothelial carcinomas and relationship with prognostic parameters. J Pathol Transl Med. 2015;49:389\u201395.","journal-title":"J Pathol Transl Med"},{"key":"3305_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00428-007-0551-z","volume":"452","author":"H-c Zheng","year":"2008","unstructured":"Zheng H-c, Takahashi H, Li X-H, Hara T, Masuda S, Guan Y-f, et al. Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas. Virchows Arch. 2008;452:147\u201355.","journal-title":"Virchows Arch"},{"key":"3305_CR14","first-page":"2426","volume":"8","author":"J-J Zhu","year":"2016","unstructured":"Zhu J-J, Cui Y, Cui K, Li X, Zhang Z-Y. Distinct roles of parafibromin in the extracellular environment, cytoplasm and nucleus of osteosarcoma cells. Am J Transl Res. 2016;8:2426\u201331.","journal-title":"Am J Transl Res"},{"key":"3305_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bbrc.2006.08.169","volume":"350","author":"C Zhang","year":"2006","unstructured":"Zhang C, Kong D, Tan M-H, Pappas DL Jr, Wang P-F, Chen J, et al. Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochem Biophys Res Commun. 2006;350:17\u201324.","journal-title":"Biochem Biophys Res Commun"},{"key":"3305_CR16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/nar\/gkp991","volume":"38","author":"Y-J Yang","year":"2010","unstructured":"Yang Y-J, Han J-W, Youn H-D, Cho E-J. The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repression. Nucleic Acids Res. 2010;38:382\u201390.","journal-title":"Nucleic Acids Res"},{"key":"3305_CR17","doi-asserted-by":"publisher","first-page":"115.","DOI":"10.3390\/biom12010115","volume":"12","author":"L Jiang","year":"2022","unstructured":"Jiang L, Chen W, Ye J, Wang Y. Potential role of exosomes in ischemic stroke treatment. Biomolecules. 2022;12:115.","journal-title":"Biomolecules"},{"key":"3305_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.omto.2021.02.007","volume":"20","author":"A Labani-Motlagh","year":"2021","unstructured":"Labani-Motlagh A, Naseri S, Wenthe J, Eriksson E, Loskog A. Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes. Mol Ther-Oncolytics. 2021;20:508\u201318.","journal-title":"Mol Ther-Oncolytics"},{"key":"3305_CR19","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.7150\/thno.22952","volume":"8","author":"K Huang","year":"2018","unstructured":"Huang K, Fang C, Yi KK, Liu X, Qi HZ, Tan YL, et al. The role of PTRF\/Cavin1 as a biomarker in both glioma and serum exosomes. Theranostics. 2018;8:1540\u201357.","journal-title":"Theranostics"},{"key":"3305_CR20","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:640.","journal-title":"Science"},{"key":"3305_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2017.08.003","volume":"407","author":"L Zhou","year":"2017","unstructured":"Zhou L, Lv TF, Zhang Q, Zhu QQ, Zhan P, Zhu SH, et al. The biology, function and clinical implications of exosomes in lung cancer. Cancer Lett. 2017;407:84\u201392.","journal-title":"Cancer Lett"},{"key":"3305_CR22","doi-asserted-by":"publisher","first-page":"454.","DOI":"10.1038\/s41419-018-0485-1","volume":"9","author":"X Dai","year":"2018","unstructured":"Dai X, Chen C, Yang Q, Xue J, Chen X, Sun B, et al. Exosomal circRNA_100284 from arsenite-transformed cells, via microRNA-217 regulation of EZH2, is involved in the malignant transformation of human hepatic cells by accelerating the cell cycle and promoting cell proliferation. Cell Death Dis. 2018;9:454.","journal-title":"Cell Death Dis"},{"key":"3305_CR23","doi-asserted-by":"publisher","first-page":"5983629.","DOI":"10.1155\/2022\/5983629","volume":"2022","author":"F Wu","year":"2022","unstructured":"Wu F, Yang J, Shang G, Zhang Z, Niu S, Liu Y, et al. Exosomal miR-224-5p from colorectal cancer cells promotes malignant transformation of human normal colon epithelial cells by promoting cell proliferation through downregulation of CMTM4. Oxid Med Cell Longev. 2022;2022:5983629.","journal-title":"Oxid Med Cell Longev"},{"key":"3305_CR24","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00204-014-1291-x","volume":"89","author":"Y Xu","year":"2015","unstructured":"Xu Y, Luo F, Liu Y, Shi L, Lu X, Xu W, et al. Exosomal miR-21 derived from arsenite-transformed human bronchial epithelial cells promotes cell proliferation associated with arsenite carcinogenesis. Arch Toxicol. 2015;89:1071\u201382.","journal-title":"Arch Toxicol"},{"key":"3305_CR25","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0960-9822(07)00493-9","volume":"8","author":"D Haas-Kogan","year":"1998","unstructured":"Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. Protein kinase B (PKB\/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN\/MMAC. Curr Biol. 1998;8:1195\u20138.","journal-title":"Curr Biol"},{"key":"3305_CR26","doi-asserted-by":"publisher","first-page":"4332.","DOI":"10.1038\/s41467-019-12184-8","volume":"10","author":"R-C Wu","year":"2019","unstructured":"Wu R-C, Young I-C, Chen Y-F, Chuang S-T, Toubaji A, Wu M-Y. Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer. Nat Commun. 2019;10:4332.","journal-title":"Nat Commun"},{"key":"3305_CR27","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1158\/0008-5472.CAN-10-2221","volume":"71","author":"K Sasai","year":"2011","unstructured":"Sasai K, Sukezane T, Yanagita E, Nakagawa H, Hotta A, Itoh T, et al. Oncogene-mediated human lung epithelial cell transformation produces adenocarcinoma phenotypes in vivo. Cancer Res. 2011;71:2541\u20139.","journal-title":"Cancer Res"},{"key":"3305_CR28","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1158\/1541-7786.MCR-12-0634-T","volume":"11","author":"M Sato","year":"2013","unstructured":"Sato M, Larsen JE, Lee W, Sun H, Shames DS, Dalvi MP, et al. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res. 2013;11:638\u201350.","journal-title":"Mol Cancer Res"},{"key":"3305_CR29","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s12276-022-00855-4","volume":"54","author":"X Wang","year":"2022","unstructured":"Wang X, Huang J, Chen W, Li G, Li Z, Lei J. The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer. Exp Mol Med. 2022;54:1390\u2013400.","journal-title":"Exp Mol Med"},{"key":"3305_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41416-020-01149-0","volume":"124","author":"NM Novikov","year":"2021","unstructured":"Novikov NM, Zolotaryova SY, Gautreau AM, Denisov EV. Mutational drivers of cancer cell migration and invasion. Br J Cancer. 2021;124:102\u201314.","journal-title":"Br J Cancer"},{"key":"3305_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10555-023-10141-y","volume":"43","author":"D Singh","year":"2024","unstructured":"Singh D, Siddique HR. Epithelial-to-mesenchymal transition in cancer progression: unraveling the immunosuppressive module driving therapy resistance. Cancer Metastasis Rev. 2024;43:155\u201373.","journal-title":"Cancer Metastasis Rev"},{"key":"3305_CR32","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1590\/1519-6984.228437","volume":"81","author":"E Obeng","year":"2021","unstructured":"Obeng E. Apoptosis (programmed cell death) and its signals\u2014a review. Braz J Biol. 2021;81:1133\u201343.","journal-title":"Braz J Biol"},{"key":"3305_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22:138.","journal-title":"Mol Cancer"},{"key":"3305_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.canlet.2005.11.042","volume":"241","author":"LM Chow","year":"2006","unstructured":"Chow LM, Baker SJ. PTEN function in normal and neoplastic growth. Cancer Lett. 2006;241:184\u201396.","journal-title":"Cancer Lett"},{"key":"3305_CR35","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.cell.2015.04.042","volume":"161","author":"A Zomer","year":"2015","unstructured":"Zomer A, Maynard C, Verweij FJ, Kamermans A, Schafer R, Beerling E, et al. In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell. 2015;161:1046\u201357.","journal-title":"Cell"},{"key":"3305_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102237","volume":"99","author":"L Succony","year":"2021","unstructured":"Succony L, Rassl DM, Barker AP, McCaughan FM, Rintoul RC. Adenocarcinoma spectrum lesions of the lung: detection, pathology and treatment strategies. Cancer Treat Rev. 2021;99:102237.","journal-title":"Cancer Treat Rev"},{"key":"3305_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/jdi.12369","volume":"7","author":"T Hosooka","year":"2016","unstructured":"Hosooka T, Ogawa W. A novel role for the cell cycle regulatory complex cyclin D1-CDK4 in gluconeogenesis. J Diab Investig. 2016;7:27\u20138.","journal-title":"J Diab Investig"},{"key":"3305_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.molonc.2011.11.002","volume":"6","author":"X Ding","year":"2012","unstructured":"Ding X, Zhang N, Cai Y, Li S, Zheng C, Jin Y, et al. Down-regulation of tumor suppressor MTUS1\/ATIP is associated with enhanced proliferation, poor differentiation and poor prognosis in oral tongue squamous cell carcinoma. Mol Oncol. 2012;6:73\u201380.","journal-title":"Mol Oncol"},{"key":"3305_CR39","doi-asserted-by":"publisher","first-page":"e0252932.","DOI":"10.1371\/journal.pone.0252932","volume":"16","author":"LT Rozario","year":"2021","unstructured":"Rozario LT, Sharker T, Nila TA. In silico analysis of deleterious SNPs of human MTUS1 gene and their impacts on subsequent protein structure and function. PLoS ONE. 2021;16:e0252932.","journal-title":"PLoS ONE"},{"key":"3305_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41392-020-0123-0","volume":"5","author":"K Lu","year":"2020","unstructured":"Lu K, Li B, Zhang H, Xu Z, Song D, Gao L, et al. A novel silicone derivative of natural osalmid (DCZ0858) induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma via the JAK2\/STAT3 pathway. Signal Transduct Target Ther. 2020;5:31.","journal-title":"Signal Transduct Target Ther"},{"key":"3305_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15:129.","journal-title":"J Hematol Oncol"},{"key":"3305_CR42","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13046-014-0062-0","volume":"33","author":"S Kaufhold","year":"2014","unstructured":"Kaufhold S, Bonavida B. Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res. 2014;33:62.","journal-title":"J Exp Clin Cancer Res"},{"key":"3305_CR43","doi-asserted-by":"publisher","first-page":"F1263","DOI":"10.1152\/ajprenal.00475.2009","volume":"298","author":"YJ Lee","year":"2010","unstructured":"Lee YJ, Han HJ. Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K\/Akt, GSK-3 beta, Snail1, and beta-catenin in renal proximal tubule cells. Am J Physiol Ren Physiol. 2010;298:F1263\u2013F75.","journal-title":"Am J Physiol Ren Physiol"},{"key":"3305_CR44","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S0002-9440(10)63692-9","volume":"163","author":"B Nawrocki-Raby","year":"2003","unstructured":"Nawrocki-Raby B, Gilles C, Polette M, Martinella-Catusse C, Bonnet N, Puchelle E, et al. E-cadherin mediates MMP down-regulation in highly invasive bronchial tumor cells. Am J Pathol. 2003;163:653\u201361.","journal-title":"Am J Pathol"},{"key":"3305_CR45","doi-asserted-by":"publisher","first-page":"3464.","DOI":"10.3390\/ijms22073464","volume":"22","author":"R Mishra","year":"2021","unstructured":"Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22:3464.","journal-title":"Int J Mol Sci"},{"key":"3305_CR46","doi-asserted-by":"publisher","first-page":"21138","DOI":"10.3390\/ijms160921138","volume":"16","author":"S Faes","year":"2015","unstructured":"Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. Int J Mol Sci. 2015;16:21138\u201352.","journal-title":"Int J Mol Sci"},{"key":"3305_CR47","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1111\/cas.14660","volume":"111","author":"Y Matsumoto","year":"2020","unstructured":"Matsumoto Y, Kano M, Murakami K, Toyozumi T, Suito H, Takahashi M, et al. Tumor-derived exosomes influence the cell cycle and cell migration of human esophageal cancer cell lines. Cancer Sci. 2020;111:4348\u201358.","journal-title":"Cancer Sci"},{"key":"3305_CR48","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s12015-021-10185-z","volume":"18","author":"K Malekpour","year":"2022","unstructured":"Malekpour K, Hazrati A, Zahar M, Markov A, Zekiy AO, Navashenaq JG, et al. The potential use of mesenchymal stem cells and their derived exosomes for orthopedic diseases treatment. Stem Cell Rev Rep. 2022;18:933\u201351.","journal-title":"Stem Cell Rev Rep"},{"key":"3305_CR49","doi-asserted-by":"publisher","first-page":"103.","DOI":"10.1186\/s12951-018-0429-z","volume":"16","author":"H Li","year":"2018","unstructured":"Li H, Yang C, Shi Y, Zhao L. Exosomes derived from siRNA against GRP78 modified bone-marrow-derived mesenchymal stem cells suppress Sorafenib resistance in hepatocellular carcinoma. J Nanobiotechnol. 2018;16:103.","journal-title":"J Nanobiotechnol"},{"key":"3305_CR50","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jhep.2023.02.027","volume":"79","author":"A Lapitz","year":"2023","unstructured":"Lapitz A, Azkargorta M, Milkiewicz P, Olaizola P, Zhuravleva E, Grimsrud MM, et al. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma. J Hepatol. 2023;79:93\u2013108.","journal-title":"J Hepatol"},{"key":"3305_CR51","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.devcel.2022.01.002","volume":"57","author":"W Zhang","year":"2022","unstructured":"Zhang W, Zhong W, Wang B, Yang J, Yang J, Yu Z, et al. ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression. Dev Cell. 2022;57:329.","journal-title":"Dev Cell"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03305-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03305-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03305-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:01:47Z","timestamp":1791583307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03305-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3305"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-03305-6","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The study was approved by the Ethics Committee of the Affiliated Hospital 2 of Nantong University and Jinling Hospital Affiliated with Nanjing University (2022DZGKJDWLS-0014, 2022DZGZR-050). Written informed consent was obtained from all participants prior to their participation in the study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"412"}}